Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02578030 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02578030 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 27 participants.
The verdict
NCT02578030, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
To provide additional, required information on the pharmacokinetic profile of SHP465 in the targeted population (children and adolescents aged 6-17 years of age with ADHD).
Interventions
- DRUG SHP465 12.5mg
- DRUG SHP465 25mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-10-24 |
| Est. Completion | 2015-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02578030
The ClinicalTrials.gov registry entry for NCT02578030 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SHP465 12.5mg is the first listed.
NCT02578030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02578030 about?
NCT02578030 is a clinical study titled "Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD". To provide additional, required information on the pharmacokinetic profile of SHP465 in the targeted population (children and adolescents aged 6-17 years of age with ADHD).
What is the current status of trial NCT02578030?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-10-24. Estimated completion is 2015-11-10.
What interventions are being tested in trial NCT02578030?
The interventions under investigation include: SHP465 12.5mg (DRUG), SHP465 25mg (DRUG).
Who is sponsoring clinical trial NCT02578030?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.